Despite a lack of conclusive research results, the Food and Drug Administration alerted physicians that treating women for obesity with a combination of fenfluramine and phentermine may be linked to valvular heart disease.
Despite a lack of conclusive research results, the Food and Drug Administration alerted physicians that treating women for obesity with a combination of fenfluramine and phentermine may be linked to valvular heart disease.
According to a letter mail-ed to physicians, the FDA has received reports of 33 cases of unusual abnormalities in mitral, aortic and tricuspid heart valves in women who had been taking fenfluramine and phentermine for one month to 28 months. The women were between the ages of 30 and 72 and were healthy aside from obesity.
The FDA said it has found no conclusive evidence of a cause-and-effect relationship between use of the products and the development of valvular disease, but the agency stated that the seriousness of the cardiac problems prompted it to notify physicians. Researchers at the Mayo Clinic and Mayo Foundation, Rochester, MN, announced that they will publish the results of a study on the combined drugs and valvular disease in the August issue of the New England Journal of Medicine.
Both drugs were individually approved more than 20 years ago as single-drug, short-term obesity treatments. In recent years, however, doctors have paired the two for the long-term management of obesity. The FDA has never indicated that the drugs should be combined for that use.
Manufacturers of the products, including American Home Products, Madison, NJ, and SmithKline Beecham, Philadelphia, have been asked to meet with the FDA to discuss possible labeling changes.
In addition, the agency asked that all health care professionals report any cases of cardiac valvular disease or other serious toxicities associated with use of fenfluramine, phentermine or dexfenfluramine to the manufacturers or to the FDA at, (800) FDA-1088. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.